A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers
Phase 1
Active, not recruiting
- Conditions
- Pancreatic CancerColorectal CancerGastric CancerOvarian Cancer
- Interventions
- Drug: CUE-102
- First Posted Date
- 2022-05-04
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Cue Biopharma
- Target Recruit Count
- 52
- Registration Number
- NCT05360680
- Locations
- 🇺🇸
Stanford Advanced Medicine Cancer Center, Palo Alto, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Phase 1
Active, not recruiting
- Conditions
- Head and Neck CancerHPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Related Carcinoma
- Interventions
- Drug: CUE-101Drug: KEYTRUDA®, Pembrolizumab
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Cue Biopharma
- Target Recruit Count
- 85
- Registration Number
- NCT03978689
- Locations
- 🇺🇸
University of Washington School of Medicine, Seattle, Washington, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
🇺🇸Affiliated Oncologists, LLC, Chicago, Illinois, United States
© Copyright 2025. All Rights Reserved by MedPath